Imunon, Inc. is a clinical-stage biotechnology company. It is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. It has two platform technologies: TheraPlas platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 works by instructing the body to produce cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, it is conducting preclinical studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus to validate its PLACCINE platform. Its platform technologies are based on the delivery of nucleic acids with synthetic delivery systems that are independent of viral vectors or devices.
